Aspen Neuroscience Announces Positive 12‑Month Data from its ASPIRO Clinical Trial in a Late‑Breaking Oral Presentation at the AD/PDTM 2026 International Conference on Alzheimer’s and Parkinson’s Diseases
Results Show Continued Safety, Tolerability, and Sustained Clinical Benefit Including Improvements in Function, Physician- and Patient-Reported Outcomes, and Quality-of-Life
This Personalized Autologous Cell Therapy Aims to Replace and Restore the Damaged Neural Circuitry in Parkinson’s Patients that Underpins Everyday Movement and Function, Without the Need for Immune Suppression
SAN DIEGO, Mar. 18, 2026 /PRNewswire/ — Aspen Neuroscience, a clinical-stage regenerative medicine company developing autologous induced-pluripotent stem cell (iPSC)-derived therapies to initially address neurodegenerative diseases with high unmet medical need, today announced data from its ongoing Phase 1/2a ASPIRO* clinical trial in a late‑breaking oral presentation at the AD/PDTM 2026 International Conference on Alzheimer’s and Parkinson’s Diseases, taking place March 17–21, 2026 in Copenhagen, Denmark.
Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites per protocol under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.
